AR121890A2 - ANTIBODIES AND METHODS OF USE - Google Patents

ANTIBODIES AND METHODS OF USE

Info

Publication number
AR121890A2
AR121890A2 ARP210101055A ARP210101055A AR121890A2 AR 121890 A2 AR121890 A2 AR 121890A2 AR P210101055 A ARP210101055 A AR P210101055A AR P210101055 A ARP210101055 A AR P210101055A AR 121890 A2 AR121890 A2 AR 121890A2
Authority
AR
Argentina
Prior art keywords
diabetes
type
disease
alcoholic steatohepatitis
antibody
Prior art date
Application number
ARP210101055A
Other languages
Spanish (es)
Inventor
Yongmei Chen
James Ernst
Hok Seon Kim
Junichiro Sonoda
Christoph Spiess
Scott Stawicki
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR121890A2 publication Critical patent/AR121890A2/en

Links

Abstract

Reivindicación 1: Un anticuerpo biespecífico aislado, o una porción de unión a antígeno del mismo, caracterizado porque se une a b-Klotho (KLB) y al Receptor del Factor de Crecimiento de Fibroblastos 1 (FGFR1). Reivindicación 44: El anticuerpo de cualquiera de las reivindicaciones 1 - 36 caracterizado porque es para uso en el tratamiento de un trastorno seleccionado del grupo que consiste en síndrome de ovario poliquístico (PCOS), síndrome metabólico (Met), obesidad, esteatohepatitis no alcohólica (NASH), esteatohepatitis no alcohólica (NAFLD), hiperlipidemia, hipertensión, diabetes tipo 2, diabetes no tipo 2, diabetes tipo 1, diabetes autoinmune latente (LAD) y diabetes de comienzo en la madurez de la juventud (MODY), y envejecimiento y enfermedades relacionadas, tales como la enfermedad de Alzheimer, enfermedad de Parkinson y ALS.Claim 1: An isolated bispecific antibody, or an antigen-binding portion thereof, characterized in that it binds b-Klotho (KLB) and Fibroblast Growth Factor Receptor 1 (FGFR1). Claim 44: The antibody of any of claims 1-36 characterized in that it is for use in the treatment of a disorder selected from the group consisting of polycystic ovary syndrome (PCOS), metabolic syndrome (Met), obesity, non-alcoholic steatohepatitis ( NASH), non-alcoholic steatohepatitis (NAFLD), hyperlipidemia, hypertension, type 2 diabetes, non-type 2 diabetes, type 1 diabetes, latent autoimmune diabetes (LAD), and maturity-onset diabetes of youth (MODY), and aging and related diseases, such as Alzheimer's disease, Parkinson's disease and ALS.

ARP210101055A 2013-12-23 2021-04-20 ANTIBODIES AND METHODS OF USE AR121890A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920396P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
AR121890A2 true AR121890A2 (en) 2022-07-20

Family

ID=58698507

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140104857A AR098915A1 (en) 2013-12-23 2014-12-22 ANTIBODIES THAT BIND B-KLOTHO (KLB) AND METHODS OF USE
ARP210101055A AR121890A2 (en) 2013-12-23 2021-04-20 ANTIBODIES AND METHODS OF USE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140104857A AR098915A1 (en) 2013-12-23 2014-12-22 ANTIBODIES THAT BIND B-KLOTHO (KLB) AND METHODS OF USE

Country Status (2)

Country Link
AR (2) AR098915A1 (en)
MA (1) MA39058B1 (en)

Also Published As

Publication number Publication date
MA39058B1 (en) 2020-08-31
AR098915A1 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
CL2014001074A1 (en) Monoclonal antibodies which is anti-binding protein at 43 kda tar DNA (tdp-43); polynucleotide that encodes it; pharmaceutical composition that contains it; antibody use.
EA201891066A1 (en) ANTIBODIES TO ROR1
CL2019001583A1 (en) New anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier.
PE20191208A1 (en) ANTI-CD73 ANTIBODIES AND USES OF THEM
UA118029C2 (en) Human fcrn-binding modified antibodies and methods of use
EA201891040A1 (en) ANTIBODY CONJUGATES CONTAINING AGENTISTS OF TALL-SIMILAR RECEPTOR
PE20221007A1 (en) ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY
UA116873C2 (en) Antibodies that bing to ox40 and their uses
EA201692458A1 (en) ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
AR081750A1 (en) ANTI-CD40 ANTIBODIES
CU24538B1 (en) MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 16G7 ANTIBODY
PE20211798A1 (en) ANTIBODIES AND CONJUGATES OF ANTIBODY AND ANTI-EGFR DRUG
UY33983A (en) Union Proteins of the Antibody Type with Dual Variable Region that Have Orientation of the Union Region with Cross-linking.
JP2013241409A5 (en)
PE20211272A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
UA115540C2 (en) Anti il-36r antibodies
CL2014000574A1 (en) Humanized monoclonal antibody that binds to the human aßtcr / cd3 complex.
UA113879C2 (en) HUMANIZED TRK ANTITILE ANTIBODY
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER
PH12016501366A1 (en) Novel anti-baff antibodies
UA117097C2 (en) Antibodies to bradykinin b1 receptor ligands
UA123202C2 (en) Antibodies to tau and uses thereof
PE20160993A1 (en) NEW ANTI-DPEP3 ANTIBODIES AND METHODS OF USE
EA201590412A1 (en) ANTIBODY COMPOSITIONS AND THEIR APPLICATIONS
PE20130207A1 (en) ANTIBODIES ANTAGONISTS TO LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS